Captrust Financial Advisors Taysha Gene Therapies, Inc. Transaction History

Captrust Financial Advisors

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	SELL	$2.47 - $6.77 $494 - $1,354	-200 Reduced 19.59%	821 $3,000
Q2 2021 Aug 16, 2021	BUY	$19.29 - $26.38 $1,157 - $1,582	60 Added 6.24%	1,021 $22,000
Q1 2021 May 17, 2021	BUY	$20.3 - $31.75 $4,892 - $7,651	241 Added 33.47%	961 $20,000
Q4 2020 Feb 16, 2021	BUY	$19.14 - $28.13 $6,699 - $9,845	350 Added 94.59%	720 $19,000
Q3 2020 Nov 17, 2020	BUY	$22.4 - $24.47 $8,288 - $9,053	370 New	370 $8,000

119

136M

25.9K

24K

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $97.2M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.